Mouse IgG2a (min X Ck,Rb,Gt,Sh,Bov,Hr,Dog,Sw,Bab Hu IgG, Hu IgG_M), Clone LOMG2a7, Rat Mab anti_, FITC

Price:
901 EUR
1081 USD
747 GBP
known as: Mouse IgG2a (min X Ck,Rb,Gt,Sh,Bov,Hr,Dog,Sw,Bab Hu IgG, Hu IgG_M), Clone LOMG2a7, Rat Mab anti_, FITC
Catalog number: genta-YULLOMG2a7-F1
Product Quantity: 1 ml.
Category:
Supplier: Accu

   CAPTCHA Image   Reload Image

Gene target: igg2a min x ck rb gt sh bov hr sw bab hu m clone lomg2a7 mab

Related genes to: Mouse IgG2a (min X Ck,Rb,Gt,Sh,Bov,Hr,Dog,Sw,Bab Hu IgG, Hu IgG_M), Clone LOMG2a7, Rat Mab anti_, FITC

Symbol : dog NIH gene
dbXrefs : FLYBASE:FBgn0016793
chromosome : 3
map location : 3-42 cM
description : dog of glass
type of gene : unknown
Modification date : 2016-05-09
Symbol : IGG NIH gene
dbXrefs : AnimalQTLdb:17939
chromosome : 2
map location : 2 0.2 cM
description : Immunoglobulin G level
type of gene : unknown
Modification date : 2015-01-24
Symbol : min NIH gene
Synonyms : mi
dbXrefs : FLYBASE:FBgn0002747
chromosome : 2
map location : 56E-56E|2-90 cM
description : mini
type of gene : unknown
Modification date : 2016-05-09

Related Pathways to: Mouse IgG2a (min X Ck,Rb,Gt,Sh,Bov,Hr,Dog,Sw,Bab Hu IgG, Hu IgG_M), Clone LOMG2a7, Rat Mab anti_, FITC

Gene about :IgG
Pathway :Mm Microglia Pathogen Phagocytosis Pathway
IgG

Related product to: Mouse IgG2a (min X Ck,Rb,Gt,Sh,Bov,Hr,Dog,Sw,Bab Hu IgG, Hu IgG_M), Clone LOMG2a7, Rat Mab anti_, FITC

Related Articles about: Mouse IgG2a (min X Ck,Rb,Gt,Sh,Bov,Hr,Dog,Sw,Bab Hu IgG, Hu IgG_M), Clone LOMG2a7, Rat Mab anti_, FITC

Symmetrical brachydactyly in a dog.

Congenital malformations of the canine manus and pes are infrequently reported in the veterinary literature. This includes brachydactyly which is a general term used to indicate the shortening of digits due to abnormal development of the phalanges, metacarpals, or metatarsals. This case report describes isolated brachydactyly in a one-year-old male Maremma Sheepdog affecting all of the phalanges, metacarpals, and metatarsals of digits two through five. This condition was confirmed by determining the length of each phalanx, metacarpal, and metatarsal of the affected dog as well as an unaffected littermate. The affected dog's metacarpal, metatarsal, and phalanx lengths ranged from 50% to 77% of that of the unaffected sibling. Other abnormalities found on physical examination as well as on radiographic imaging are discussed. - Source :PubMed

HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs.

The anti-HLA-E IgG2a mAbs, TFL-006 and TFL-007, reacted with all HLA-I antigens, similar to the therapeutic preparations of IVIg. Indeed, IVIg lost its HLA reactivity, when its HLA-E reactivity was adsorbed out. US-FDA approved IVIg to reduce antibodies in autoimmune diseases. But the mechanism underlying IVIg-mediated antibody reduction could not be ascertained due to the presence of other polyclonal antibodies. In spite of it, the cost prohibitive high or low IVIg is administered to patients waiting for donor organ and for allograft recipients for lowering antiallograft antibodies. A mAb that could mimic IVIg in lowering Abs, with defined mechanism of action, would be highly beneficial for patients. Demonstrably, the anti-HLA-E mAbs mimicked several functions of IVIg relevant to suppressing the antiallograft Abs. The mAbs suppressed activated T cells and anti-HLA antibody production by activated B cells, which were dose-wise superior to IVIg. The anti-HLA-E mAb expanded CD4+, CD25+, and Foxp(3)+ Tregs, which are known to suppress T and B cells involved in antibody production. These defined functions of the anti-HLA-E IgG2a mAbs at a level superior to IVIg encourage developing their humanized version to lower antibodies in allograft recipients, to promote graft survival, and to control autoimmune diseases. - Source :PubMed

Anti-Fas2 IgM antibodies in Fasciola hepatica infected patients with positive IgG serology.

Fascioliasis is an infectious disease caused by parasites Fasciola hepatica and F. gigantica. Humans are infected by the consumption of vegetables and water contaminated with the infective form of the parasite. - Source :PubMed

Cryptococcal Maxillary Osteomyelitis and Osteonecrosis in a 18-Month-Old Dog.

An 18-month-old neutered male labradoodle was treated with surgical debridement for maxillary osteomyelitis and sequestrum formation. Histopathologic findings of the necrotic bone were consistent with Cryptococcus subspecies, confirmed with latex agglutination serum titer testing. The patient responded to a combination of fluconazole and surgical debridement and was titer negative after 8 months of medical therapy. The patient never exhibited signs of systemic illness which is commonly reported with cryptococcosis. Cryptococcus subspecies infection in dogs in the Pacific Northwest is part of an ongoing outbreak in the region, first reported in 2001, and is associated with specific risk factors. This is the first published case of oral cryptococcosis from primary inoculation. - Source :PubMed

Semilunar Coronally Advanced Periodontal Flap to Increase Soft Tissue Coverage of a Maxillary Fourth Premolar in a Dog.

A 7-year-old, 31.3 kg spayed female Golden Retriever dog was presented for the treatment of Miller Class I gingival recession at the right maxillary fourth premolar (108). A semilunar coronally advanced periodontal flap was performed at this tooth and created an increase of approximately 3 mm of soft tissue coverage of the tooth. This method may have benefits over traditional periodontal advancement flaps in that there is no need for suturing, can be done more quickly, maintains lateral blood supply to the flap, and likely has decreased risk of surgical site dehiscence. This case shows that the semilunar coronally advanced periodontal flap demonstrates an appropriate method to treat Miller Class I gingival recession in the maxilla. - Source :PubMed

Gentaur adresses


GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
Fax 0032 16 50 90 45
info@gentaur.com
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
france@gentaur.com
dimi@gentaur.com
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531
Fax 020 8445 9411
uk@gentaur.com
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
poland@gentaur.com
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893
Fax 0497-517897
nl@gentaur.com
GENTAUR SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com
GENTAUR bulgaria
53 Iskar Str. Kokalyane,
Sofia 1191
Tel 0035929830070
Fax 0035929830072
sofia@gentaur.com
GENTAUR Spain
Tel 0911876558
spain@gentaur.com
GENTAUR USA
Genprice Inc, Logistics
547 Yurok Circle
San Jose, CA 95123
invoicing/ accounting:
6017 Snell Ave, Suite 357
San Jose, CA. 96123
Tel 001 408 780 0908
jane@gentaur.com